Overview

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

This trial will assess the safety and efficacy of OPC-167832 combined with Delamanid and Bedaquiline in subjects with DS-TB administered for 4 months compared to rifampin, isoniazid, ethambutol, pyrazinamide (RHEZ) administered for 6 months

Phase:

Phase 2

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborator:

Bill and Melinda Gates Foundation

Treatments:

Bedaquiline
Diarylquinolines